| Apollo Healthcare, Llc | |
|
1031 E Karsch Blvd Farmington MO 63640-3404 | |
| (573) 756-7880 | |
| (573) 756-2669 |
| Full Name | Apollo Healthcare, Llc |
|---|---|
| Speciality | Clinic/Center |
| Location | 1031 E Karsch Blvd, Farmington, Missouri |
| Authorized Official Name and Position | Amelia Doris Ledbetter (DIRECTOR) |
| Authorized Official Contact | 5733354715 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Apollo Healthcare, Llc Po Box 107 Farmington MO 63640-0107 Ph: (573) 756-7880 | Apollo Healthcare, Llc 1031 E Karsch Blvd Farmington MO 63640-3404 Ph: (573) 756-7880 |
| NPI Number | 1245545391 |
|---|---|
| Provider Enumeration Date | 08/13/2010 |
| Last Update Date | 09/19/2023 |
| Medicare PECOS PAC ID | 4385823335 |
|---|---|
| Medicare Enrollment ID | O20110124000942 |
News Archive
Sorrento Therapeutics, Inc. announced today the entry into a definitive agreement to acquire San Diego-based Concortis Biosystems, Corp. in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody drug conjugates (ADC). Under the terms of the agreement dated November 11, 2013, subject to satisfaction of certain closing conditions, upon closing, Sorrento will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders.
Most tumors contain regions of low oxygen concentration where cancer therapies based on the action of reactive oxygen species are ineffective.
An accurate, up to the minute, accessible medical record system is fundamental to effective treatment and tracking of the Ebola virus.
St. Jude Children's Research Hospital scientists have a lead on reducing life-threatening respiratory problems in infants born to women who develop the liver disorder intrahepatic cholestasis of pregnancy (ICP).
ACCESS PHARMACEUTICALS, INC., today announced that it has completed enrollment and evaluation of the last additional cohort of patients in the ongoing clinical study of ProLindac as a monotherapy in ovarian cancer patients who have received at least two prior platinum based treatment regimens.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245545391 | NPI | - | NPPES |
| 590121307 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QR1300X | Clinic/center - Rural Health | (* (Not Available)) | Primary |
| Provider Name | Nilima P Chand |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1942227681 PECOS PAC ID: 6103729967 Enrollment ID: I20071107000718 |
News Archive
Sorrento Therapeutics, Inc. announced today the entry into a definitive agreement to acquire San Diego-based Concortis Biosystems, Corp. in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody drug conjugates (ADC). Under the terms of the agreement dated November 11, 2013, subject to satisfaction of certain closing conditions, upon closing, Sorrento will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders.
Most tumors contain regions of low oxygen concentration where cancer therapies based on the action of reactive oxygen species are ineffective.
An accurate, up to the minute, accessible medical record system is fundamental to effective treatment and tracking of the Ebola virus.
St. Jude Children's Research Hospital scientists have a lead on reducing life-threatening respiratory problems in infants born to women who develop the liver disorder intrahepatic cholestasis of pregnancy (ICP).
ACCESS PHARMACEUTICALS, INC., today announced that it has completed enrollment and evaluation of the last additional cohort of patients in the ongoing clinical study of ProLindac as a monotherapy in ovarian cancer patients who have received at least two prior platinum based treatment regimens.
› Verified 6 days ago
| Provider Name | Laurie Ann Heaps |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1922295633 PECOS PAC ID: 8820175409 Enrollment ID: I20080407000394 |
News Archive
Sorrento Therapeutics, Inc. announced today the entry into a definitive agreement to acquire San Diego-based Concortis Biosystems, Corp. in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody drug conjugates (ADC). Under the terms of the agreement dated November 11, 2013, subject to satisfaction of certain closing conditions, upon closing, Sorrento will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders.
Most tumors contain regions of low oxygen concentration where cancer therapies based on the action of reactive oxygen species are ineffective.
An accurate, up to the minute, accessible medical record system is fundamental to effective treatment and tracking of the Ebola virus.
St. Jude Children's Research Hospital scientists have a lead on reducing life-threatening respiratory problems in infants born to women who develop the liver disorder intrahepatic cholestasis of pregnancy (ICP).
ACCESS PHARMACEUTICALS, INC., today announced that it has completed enrollment and evaluation of the last additional cohort of patients in the ongoing clinical study of ProLindac as a monotherapy in ovarian cancer patients who have received at least two prior platinum based treatment regimens.
› Verified 6 days ago
| Provider Name | Linda Hunter |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1760765804 PECOS PAC ID: 3274708706 Enrollment ID: I20111213000238 |
News Archive
Sorrento Therapeutics, Inc. announced today the entry into a definitive agreement to acquire San Diego-based Concortis Biosystems, Corp. in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody drug conjugates (ADC). Under the terms of the agreement dated November 11, 2013, subject to satisfaction of certain closing conditions, upon closing, Sorrento will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders.
Most tumors contain regions of low oxygen concentration where cancer therapies based on the action of reactive oxygen species are ineffective.
An accurate, up to the minute, accessible medical record system is fundamental to effective treatment and tracking of the Ebola virus.
St. Jude Children's Research Hospital scientists have a lead on reducing life-threatening respiratory problems in infants born to women who develop the liver disorder intrahepatic cholestasis of pregnancy (ICP).
ACCESS PHARMACEUTICALS, INC., today announced that it has completed enrollment and evaluation of the last additional cohort of patients in the ongoing clinical study of ProLindac as a monotherapy in ovarian cancer patients who have received at least two prior platinum based treatment regimens.
› Verified 6 days ago
News Archive
Sorrento Therapeutics, Inc. announced today the entry into a definitive agreement to acquire San Diego-based Concortis Biosystems, Corp. in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody drug conjugates (ADC). Under the terms of the agreement dated November 11, 2013, subject to satisfaction of certain closing conditions, upon closing, Sorrento will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders.
Most tumors contain regions of low oxygen concentration where cancer therapies based on the action of reactive oxygen species are ineffective.
An accurate, up to the minute, accessible medical record system is fundamental to effective treatment and tracking of the Ebola virus.
St. Jude Children's Research Hospital scientists have a lead on reducing life-threatening respiratory problems in infants born to women who develop the liver disorder intrahepatic cholestasis of pregnancy (ICP).
ACCESS PHARMACEUTICALS, INC., today announced that it has completed enrollment and evaluation of the last additional cohort of patients in the ongoing clinical study of ProLindac as a monotherapy in ovarian cancer patients who have received at least two prior platinum based treatment regimens.
› Verified 6 days ago
Saint Francis Medical Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 515 Maple Valley Dr, Farmington, MO 63640 Phone: 573-760-7920 Fax: 573-576-9597 | |
Parkland Health Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1105 W Liberty St, Ste 4050, Farmington, MO 63640 Phone: 573-756-7844 Fax: 573-756-9597 | |
Mineral Area Primary Care Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 764 Weber Rd, Farmington, MO 63640 Phone: 573-756-2123 Fax: 573-756-2761 | |
Mineral Area Doctors Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1103 Weber Rd Ste 202, Farmington, MO 63640 Phone: 573-756-3662 Fax: 573-756-3640 | |
Great Mines Health Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1040 Forster St Rm E2a, Farmington, MO 63640 Phone: 573-438-9355 | |
Great Mines Health Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 608 Pine St Ofc 2, Farmington, MO 63640 Phone: 573-438-9355 | |
Great Mines Health Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 103 Murphy Ave Rm C2, Farmington, MO 63640 Phone: 573-438-9355 |